CNS Pharmaceuticals Inc. (CNSP)
NASDAQ: CNSP
· Real-Time Price · USD
4.96
-1.07 (-17.74%)
At close: Aug 15, 2025, 3:59 PM
5.43
9.48%
After-hours: Aug 15, 2025, 07:47 PM EDT
CNS Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 3.14K | n/a | n/a | n/a | 6.36K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.1K | 1.57K | 751.00 | 752.00 | 818.00 | 953.00 | 899.00 | 1K | 1.28K | 2.38K | 2.79K | 3.21K | 3.38K | 3.49K | 3.37K | 3.21K | 3K |
Gross Profit | -1.1K | 1.57K | -751 | -752 | -818 | 5.41K | -899 | -1K | -1.28K | -2.38K | -2.79K | -3.21K | -3.38K | -3.49K | -3.37K | -3.21K | -3K |
Operating Income | -4.34M | -3.2M | -5.63M | -2.53M | -3.54M | -5.38M | -4.53M | -4.03M | -4.93M | -5.5M | -3.42M | -3.56M | -2.78M | -2.79M | -3.81M | -3.81M | -3.61M |
Interest Income | 42.55K | 26.46K | 25.23K | 1.84K | 6.73K | 7K | 12.88K | 7.8K | 5.44 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -4.3M | -3.18M | -5.61M | -2.53M | -3.54M | -5.38M | -4.52M | -4.02M | -4.93M | -5.5M | -3.42M | -3.57M | -2.78M | -2.8M | -3.81M | -3.81M | -3.61M |
Net Income | -4.3M | -3.18M | -5.61M | -2.53M | -3.54M | -5.38M | -4.52M | -4.02M | -4.93M | -5.5M | -3.42M | -3.57M | -3.15M | -2.8M | -3.81M | -3.81M | -3.61M |
Selling & General & Admin | 1.09M | 1.7M | 1.38M | 1.41M | 1.11M | 1.11M | 1.12M | 1.18M | 1.36M | 2.15M | 1.21M | 1.34M | 1.26M | 896.33K | 1.24M | 1.15M | 1.4M |
Research & Development | 3.24M | 1.5M | 4.24M | 1.12M | 2.43M | 4.27M | 3.41M | 2.85M | 3.57M | 3.35M | 2.21M | 2.22M | 1.52M | 1.9M | 2.58M | 2.66M | 2.21M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.34M | 3.2M | 5.63M | 2.53M | 3.54M | 5.38M | 4.53M | 4.03M | 4.93M | 5.5M | 3.42M | 3.56M | 2.78M | 2.79M | 3.81M | 3.81M | 3.61M |
Interest Expense | 6.21K | 2.77K | 2.26K | 4.46K | 6.63K | 2.88K | 1.84K | 3.65K | 5.44K | 2.31K | 538.00 | 1.61K | 2.57K | 2.24K | 947.00 | 2.35K | 3.75K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -818 | -953 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.34M | 3.2M | 5.63M | 2.53M | 3.54M | 5.38M | 4.53M | 4.03M | 4.93M | 5.5M | 3.42M | 3.56M | 2.78M | 2.79M | 3.81M | 3.81M | 3.61M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 226.31K | 1.84M | 1.84M | 4.03M | 5.13M | 5.13M | 6.93M | 6.44M | 3.16M | 2.46M | 2.16M | 2.16M | 2.08M | 1.41M | 1.49M | 1.33M | 1.33M |
Shares Outstanding (Diluted) | 226.31K | 1.84M | 1.84M | 4.05M | 5.15M | 5.15M | 6.93M | 6.44M | 3.16M | 2.46M | 2.22M | 2.22M | 2.15M | 1.54M | 1.52M | 1.41M | 1.36M |
EPS (Basic) | -18.96 | -27 | -3 | -624.96 | -355.8 | -3.48 | -12.96 | -12.48 | -31.08 | 88.56 | -1.08 | -1.08 | -0.84 | 156.84 | -1.68 | -1.8 | -1.8 |
EPS (Diluted) | -18.96 | -27 | -3 | -622.8 | -355.8 | -3.48 | -12.96 | -12.48 | -31.08 | 88.56 | -1.08 | -1.08 | -0.84 | 156.84 | -1.68 | -1.8 | -1.8 |
EBITDA | -4.34M | -3.17M | -5.6M | -2.53M | -3.54M | -5.37M | -4.52M | -4.02M | -4.93M | -5.5M | -3.42M | -3.56M | -3.15M | -2.79M | -3.81M | -3.81M | -3.61M |
EBIT | -4.3M | -3.17M | -5.6M | -2.53M | -3.54M | -5.37M | -4.52M | -4.02M | -4.93M | -5.5M | -3.42M | -3.56M | -2.78M | -2.79M | -3.81M | -3.81M | -3.61M |
Depreciation & Amortization | 1.1K | 985.00 | 751.00 | 752.00 | 818.00 | 953.00 | 899.00 | 1K | 1.28K | 2.38K | 2.79K | 3.21K | 3.38K | 3.49K | 3.37K | 3.21K | 3K |